Theorem Clinical Research

Ixchelsis

Eli Lilly, TVM fund invests in Ixchelsis

Friday, August 9, 2013 01:14 PM

TVM Life Science Ventures VII, a collaboration between TVM and Eli Lilly to provide venture capital to the international pharmaceutical, biopharmaceutical and medical technology industries, has announced the fund’s second investment in Ixchelsis, a clinical-stage biotechnology startup in the U.K. Ixchelsis plans to develop to proof-of-concept IX-01, an investigational compound, originally discovered at Pfizer’s U.K. R&D site, with the potential to treat the male sexual health indication premature ejaculation.

More... »



CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs